gsk to increase to 160 million packs pa , page-18

Biota is going through a massive transformation. It's really up to the board to guide the company forward, LANI negotiations are crucial. DS have said they may take it forward themselves, I hope BTA makes the right move... I hope they don't licence the ROW rights to DS for peanuts. Either help fund a global roll-out or make sure a fantastic license deal is struck with DS. If this was to be licensed to a global pharma then a large upfront payment and excellent royalty figure is possible. It's time for BTA management to make up for past mistakes... this is your time to reward shareholders. LANI!